Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics

Biospace

Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics

Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.

Sonoma, based in South San Francisco, is developing regulatory T cell (Treg) therapies for autoimmune and degenerative diseases. The company publicly launched this morning with $40 million in its Series A financing that will support next-generation research, development and manufacturing capabilities in cell therapy and genetic engineering…..